Vida Ventures
Venture capitalLos Angeles · Pre-Seed–Late Stage · 31 people tracked
Investment thesis
Vida Ventures advances transformative biomedical innovations with the potential to create meaningful patient impact. The firm is founded on scientific expertise and operational experience across the biomedical development continuum, from discovery through commercial stage. Vida invests flexibly across stages and therapeutic areas, leveraging its team's deep knowledge of both early-stage startups and mature enterprises to support breakthrough innovations in therapeutics.
Source: firm website, verified Jul 21, 2026.
Team · 31 people
from the firm's website
Visionary entrepreneur and researcher with 30+ years in science, medicine, and venture capital. Founded multiple successful biopharmaceutical companies including Kite Pharma (acquired by Gilead) and serves as Executive Chairman of Allogene Therapeutics. Holds the Roy and Carol Doumani Chair in Urologic Oncology at UCLA.
Physician-scientist with 30+ years in medicine, research, and venture capital. Co-Founder and founding partner of TPG Biotechnology. Tenured professor at UCSF in multiple departments with over 200 peer-reviewed publications. Elected to Institute of Medicine and American Academy of Arts and Sciences.
Venture investor and entrepreneur with 18+ years in company formation and life sciences investing. Co-Founder and Partner of Two River and Co-Founder and Director of Allogene Therapeutics. Co-Founder and Director of Kite Pharma until its acquisition by Gilead.
Finance and investment professional with 30+ years in corporate finance and entrepreneurship. Founded and leads Wildcat Capital Management. Previously Managing Director at Soros Fund Management and served as co-head of the Private Equity group. Director of multiple public and private company boards.
Biotech entrepreneur and investor with 12+ years of experience co-founding and scaling companies. Former Partner at MPM BioImpact, he has cofounded multiple biotech ventures including Evelo Biosciences (IPO) and holds expertise in RNA medicines, drug discovery, and company creation.
Senior executive with 35+ years in biotechnology leadership. Previously a Partner at The Column Group and Executive Vice President at Kite Pharma, where she led business development initiatives. Serves on the boards of multiple biotech companies.
Healthcare investment professional with 25+ years of experience. Led portfolio management of flagship healthcare funds at JP Morgan Asset Management including the JP Morgan Global Healthcare Fund and managed growth-focused healthcare investments across multiple market segments.
Physician and investor with 20+ years in science and medicine. Served as Chief Medical Officer at Kite Pharma and Global Development Leader at Amgen. Active as investor-operator since 2019, serving on boards of biotech companies.
Life sciences consultant and researcher with 10+ years of expertise in chemical biology, immunology, and peptide drug discovery. Previously a Senior Life Sciences Specialist at L.E.K. Consulting working with biopharma clients. Ph.D. from MIT in immunology and drug development.
Scientist and consultant with 10+ years of experience in medicine and life sciences. Completed postdoctoral research at Harvard Medical School on gene therapy and neuroscience. Previously worked at Boston Consulting Group advising biopharma and private equity clients on R&D and investment strategy.
Life sciences researcher with 10+ years of expertise in regenerative medicine, gene therapy, and cancer biology. Postdoctoral Fellow at Harvard in stem cell and regenerative medicine with deep knowledge of genetic medicines across oncology and rare disease.
Life sciences researcher with 10+ years in neuroscience, developmental biology, and stem cell research. Ph.D. from Harvard Medical School where he also co-founded Activate Bio, a venture program for academic life science entrepreneurs. Focuses on oncology, immunology, and rare disease investments.
Investor relations and capital formation professional with 10+ years of experience. Previously Associate Director of Business Development at Commonfund working on venture capital fundraising. Specializes in private market mandates across diverse institutional investor bases.
Executive support professional with 12+ years of experience. Responsible for daily operations of executives and coordination of administrative functions. Previously worked as Executive Assistant to co-founders and CFO at multiple investment firms.
Operations and strategy professional with 10+ years in academia, medical devices, and biotech. Previously part of corporate strategy team at Kite Pharma supporting CEO and executive leadership. Co-founder of Y Combinator-backed medical device company with Ph.D. in Mechanical Engineering from UCLA.
Operations and executive support professional with 20+ years of experience in logistics, project management, and administrative functions. Expertise in relationship management, project coordination, and high-level executive support across financial and consulting sectors.
Marketing and events professional with 7+ years of experience. Supports investor relations, portfolio communications, and fundraising efforts while managing event execution. Previously coordinated events and provided administrative support at Bottleneck Management.
Accounting professional with 3+ years in accounting and investment operations. Experience in private equity fund administration and financial reporting. Previously worked in fund administration and financial services roles.
Communications executive with 25+ years in life sciences industry. Previously Senior Vice President of Corporate Communications and Investor Relations at Kite Pharma. Developed integrated communication strategies for companies with novel therapies and held senior roles at major healthcare agencies.
Accounting professional with 18+ years in investment accounting and partnership operations. Experienced in fund administration, financial reporting, and consulting. Previously held accounting roles at family offices and high-wealth management entities.
Physician-scientist with 30+ years in medicine and company building. Co-Founder and former President/CEO of Allogene Therapeutics. Previously Executive Vice President of R&D and Chief Medical Officer at Kite Pharma, with leadership in developing breakthrough immunotherapies including Yescarta and Blincyto.
Legal and venture capital professional with 20+ years in life science investing. Co-Founder and Partner of Two River and Co-Founder of Kite Pharma, where he served as General Counsel and Corporate Secretary before its acquisition by Gilead.
Biotech researcher with 25+ years in drug discovery and development. Recently Chief Scientific Officer at Voyager Therapeutics. Previously led research at Alnylam Pharmaceuticals on RNA interference therapeutics and at Biogen on protein therapeutics.
Finance and operations executive with 25+ years in venture capital and life sciences. Previously SVP of Finance at Versant Ventures and Senior Director of Finance at Genentech. MBA from Harvard Business School.
Research and development leader with 30+ years in the life sciences. Former Executive Vice President of R&D and Chief Scientific Officer at Gilead Sciences, overseeing development of 25+ medicines. Recently served as President and CEO of Kronos Bio.
Distinguished researcher and academic leader with 40+ years in cancer and immunology research. University Professor at UCLA with extensive consulting experience in biotech and pharma. Member of National Academy of Sciences, American Academy of Arts and Sciences, and National Academy of Medicine.
Physician-scientist with 20+ years in medical genetics and metabolism research. Professor at UT Southwestern and member of National Academy of Medicine. Laboratory focuses on metabolic states in cancer and pediatric diseases with over 200 peer-reviewed publications.
Administration and customer service professional with 10+ years in luxury hospitality and corporate environments. Experience in office management, administrative support, and customer relations. Previously worked in premium hospitality settings including Waldorf Astoria properties.
Certified accountant with 13+ years in accounting and investment operations. Experienced in partnership accounting, private equity, fund administration, and financial reporting. Previously worked at Tarrant Management and major financial institutions.
Protein engineering researcher with 30+ years of experience. Bren Professor at Caltech with joint appointments in biology and chemistry. Co-founder of Xencor and other computational chemistry companies. Elected to National Academy of Sciences in 2004.
Finance and accounting professional with 25+ years in private equity, venture capital, and consulting. Prior experience at TPG Capital and related entities managing financial operations and accounting functions.
What they invest in
from 26 of 41 portfolio companiesBiotech ×26Medical Devices ×18Healthtech ×7AI & Machine Learning ×5Digital Health ×4Deep Tech ×2
HQs:United States×14Denmark×1
Investments · 41 tracked
founders shown can be your intro pathAdcendo develops antibody-drug conjugates (ADCs) engineered to treat cancers with high unmet medical needs. The company translates scientific innovation into clinically differentiated medicines for patients with advanced solid tumors and other cancer types.
BiotechDigital HealthMedical Devices<UNKNOWN>, DK
Antares Therapeutics discovers and develops precision medicines, with a focus on small molecule therapies targeting previously undruggable oncology targets and other serious diseases. The company combines proprietary chemistry, target biology, and predictive sciences to advance drug candidates for cancer and other therapeutic areas.
AI & Machine LearningBiotechMedical DevicesCambridge, US
Adam Friedman(Chief Executive Officer)
Adcendo develops antibody-drug conjugates (ADCs) targeting cancers with high unmet medical need. The company engineers therapeutic medicines designed to deliver clinically differentiated outcomes for cancer patients.
BiotechMedical Devices
Aktis Oncology discovers and develops targeted radiopharmaceuticals for treating solid tumors. The company serves oncology patients and healthcare providers in the cancer care sector.
BiotechHealthtechMedical Devices
Todd Foley(Co-founder and Chairman)Patrick Baeuerle(Co-founder & Advisor)
Allogene Therapeutics develops allogeneic CAR T cell therapies (AlloCAR T) for blood cancers, solid tumors, and autoimmune diseases, using off-the-shelf manufactured cell products rather than patient-derived autologous approaches. The company aims to expand CAR T treatment access through scalable manufacturing, lower costs, and faster treatment delivery.
BiotechHealthtechMedical Devices
AskBio develops gene therapies using AAV technology to treat rare genetic diseases, including late-onset Pompe disease. The company is a wholly owned subsidiary of Bayer AG focused on advancing genetic medicine.
BiotechMedical DevicesDurham, US
Unnamed co-founder (1984)
Attovia develops precision biologics using its ATTOBODY platform for patients with immune-mediated diseases. The company creates novel complex biologic medicines through modular protein design.
BiotechDigital Health
Avalyn Pharma develops a nebulized inhalation treatment for pulmonary fibrosis designed to improve tolerability compared to existing oral therapies by directly delivering the drug to the lungs.
BiotechMedical Devices
Lyn Baranowski(CEO)
Novel T-cell engagers for immunology applications, acquired by UCB.
CandidRx develops T-cell engager antibodies to treat autoimmune diseases by redirecting T-cells to eliminate autoreactive B-cells. The company focuses on creating therapies that are more effective and easier to administer than existing antibody and cell therapy approaches.
BiotechHealthtech
Ken Song(Chairman, President and CEO)
AbbVie is a biopharmaceutical company that discovers and delivers medicines for immune-mediated diseases and other therapeutic areas globally.
BiotechHealthtechMedical Devices
Centessa Pharmaceuticals is developing an Orexin Receptor 2 Agonist program to treat sleep-wake, neurological, neurodegenerative, and neuropsychiatric disorders. The company aims to create transformational medicines for patients with these conditions.
BiotechHealthtech
Dyne Therapeutics develops targeted therapies for genetically driven neuromuscular diseases using its proprietary FORCE platform. The company focuses on discovery, clinical development, and commercialization of treatments for rare genetic disorders.
BiotechMedical DevicesWaltham, US
Johnson & Johnson is a multinational pharmaceutical corporation focused on developing innovative medicines for autoimmune, oncology, and other therapeutic areas. The company brings medical treatments and therapies to patients globally.
BiotechMedical Devices
Volastra is a clinical-stage biotechnology company developing oncology therapeutics that target chromosomal instability in cancer cells. The company uses proprietary technology and screening techniques to identify vulnerabilities in chromosomally unstable cancers and develop treatments through synthetic lethality and immune activation approaches.
BiotechNew York, US
David P. Southwell(Chief Executive Officer)
Kyverna is a clinical-stage biopharmaceutical company developing CAR T-cell therapies to treat autoimmune diseases through B cell depletion and immune system reset. The company conducts clinical trials for multiple autoimmune conditions globally.
Biotech
LB Pharma develops novel therapies for neuropsychiatric disorders, with a lead product candidate called LB-102, an oral small molecule benzamide antipsychotic targeting schizophrenia, bipolar depression, and other neuropsychiatric diseases.
BiotechDigital Health
Precision Medicine Group provides biomarker-driven research and development services and commercialization support for pharmaceutical and life science companies across drug development, manufacturing, and market access.
BiotechHealthtechMedical Devices
Quanta Therapeutics is developing orally bioavailable KRAS inhibitors for RAS-driven cancers, including candidates targeting KRASG12D, KRASG12V, and pan-KRAS mutations in pancreatic, colorectal, and endometrial cancers. The company uses conformational-sensitive assays to discover RAS-targeting therapeutics for oncology.
Biotech
Developing ultrasound-mediated nonviral genetic medicines.
Soufflé Therapeutics develops nucleic acid medicines that precisely target and deliver genetic therapeutics to specific cell types to treat disease. The company focuses on creating potent, precise medicines for patients across various disease areas through advanced delivery platforms.
AI & Machine LearningBiotechDeep Tech
Victor Kotelianski(Founder)Daniel Anderson(Founder)Robert Langer(Founder)Marino Zerial(Founder)
Tectonic is a clinical-stage biotechnology company developing therapeutic proteins and antibodies that target G-Protein Coupled Receptors (GPCRs) using a proprietary platform called GEODe™. The company focuses on therapeutic areas with significant unmet medical needs where current treatment options are limited or absent.
AI & Machine LearningBiotechMedical DevicesWatertown, US
Timothy A. Springer(Co-Founder)Andrew C. Kruse
Third Arc Bio develops breakthrough treatments in oncology and immunology through advanced biologics engineering. The company is led by a team with a track record of 35+ drug approvals.
BiotechMedical Devices
InduPro develops proximity-based therapeutics that manipulate spatial relationships of cell surface proteins to enable new disease treatments. The company specializes in protein proximity design for pharmaceutical applications.
BiotechDeep TechMedical DevicesSeattle, US
Peloton Therapeutics is a clinical-stage pharmaceutical company developing first-in-class small molecule medicines targeting HIF-2α for cancer and other life-threatening conditions, with initial focus on kidney cancer and VHL disease.
BiotechDigital HealthMedical Devices
An R&D-driven biopharmaceutical company that uses AI to develop breakthrough medicines and vaccines focused on immune system disorders across five therapeutic areas.
AI & Machine LearningBiotechMedical Devices
Alterome is a clinical-stage precision oncology company developing small molecule therapies targeting mutant KRAS and AKT E17K in cancers including non-small cell lung, pancreatic, colorectal, endometrial, and breast cancer.
BiotechHealthtechMedical DevicesSan Diego, US
ReCode develops mRNA and gene correction therapeutics for genetic diseases, using proprietary lipid nanoparticle technology to deliver treatments to specific organs. The company is focused on rare genetic conditions including cystic fibrosis and primary ciliary dyskinesia.
AI & Machine LearningBiotechMedical Devices
Dr. Daniel J. Siegwart
Board seats · per SEC filings · 2
what is this? ⓘ$95.5M raise · filed May 2026 · via Arie B. Belldegrun, Arie S. Belldegrun, Joshua A. Kazam, Joshua B. Kazam
$20.2M raise · filed Jun 2024 · via Arie S. Belldegrun, Helen S. Kim, Joshua A. Kazam
Inferred from directors named on each company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Frequently asked questions
- What stage does Vida Ventures invest at?
- Vida Ventures invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What sectors does Vida Ventures focus on?
- Vida Ventures focuses on Biotech, Deep Tech, Medical Devices.
- Where is Vida Ventures located?
- Vida Ventures is headquartered in Los Angeles, US.
Similar investors
DCVC is a deep tech venture capital firm with over a dozen years of experience backing entrepreneurs using computational approaches to solve trillion-dollar problems across industries including AI, climate, materials science, robotics, space, and biology.
F Prime Capital is an investment firm composed of scientists, engineers, physicians, operators, and investors who provide real-world expertise to help portfolio companies accelerate their path to scalable growth.
Apple Tree Partners is a life sciences venture capital firm that creates and builds transformative biotechnology companies from early-stage science through public markets. The firm works with scientists at various stages, from pre-IP ideas to company spinouts, providing capital, strategic guidance, and operational resources.
A globally recognized venture capital firm designed to provide access to highly competitive venture deals to individual investors, consistently recognized for top-decile DPI performance and as one of the most active US venture firms.
B Capital is a venture capital firm managing over $12 billion in assets with a stage-based fund approach. The firm invests across early to late-stage companies in technology, healthcare, and energy & resilience sectors, with 200+ portfolio companies and 9 global offices.